EVM
FATE icon

Eaton Vance Management’s Fate Therapeutics FATE Stock Holding History

Eaton Vance Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-545
Closed -$32K – 2094
2021
Q4 		$32K Hold
545
– – ﹤0.01% 2264
2021
Q3 		$32K Buy
545
+272
+100% +$21.3K ﹤0.01% 1584
2021
Q2 		$24K Sell
273
-12
-4% -$967 ﹤0.01% 2382
2021
Q1 		$23K Buy
+285
New +$27.3K ﹤0.01% 2018

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Eaton Vance Management's FATE Position: Q1 2022 in Review

Eaton Vance Management sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 545 shares — an estimated $32K sold.

Eaton Vance Management first reported a position in FATE in Q1 2021 and held it in 4 quarters. The position peaked at $32K in Q4 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Eaton Vance Management reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 545 Fate Therapeutics shares in Q1 2022, an estimated $32K.
  • Eaton Vance Management first reported a position in Fate Therapeutics in Q1 2021 and held it in 4 quarters.
  • Eaton Vance Management's Fate Therapeutics position peaked at $32K in Q4 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.